142 related articles for article (PubMed ID: 9067410)
41. Secreted type of modified interleukin-18 gene transduced into mouse renal cell carcinoma cells induces systemic tumor immunity.
Hara S; Nagai H; Miyake H; Yamanaka K; Arakawa S; Ichihashi M; Kamidono S; Hara I
J Urol; 2001 Jun; 165(6 Pt 1):2039-43. PubMed ID: 11371924
[TBL] [Abstract][Full Text] [Related]
42. Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice.
Croce M; Corrias MV; Orengo AM; Brizzolara A; Carlini B; Borghi M; Rigo V; Pistoia V; Ferrini S
Int J Cancer; 2010 Sep; 127(5):1141-50. PubMed ID: 20039320
[TBL] [Abstract][Full Text] [Related]
43. In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells.
Hoshino T; Yagita H; Ortaldo JR; Wiltrout RH; Young HA
Eur J Immunol; 2000 Jul; 30(7):1998-2006. PubMed ID: 10940889
[TBL] [Abstract][Full Text] [Related]
44. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.
Hillman GG; Reich LA; Rothstein SE; Abernathy LM; Fountain MD; Hankerd K; Yunker CK; Rakowski JT; Quemeneur E; Slos P
J Immunother Cancer; 2017; 5():4. PubMed ID: 28116088
[TBL] [Abstract][Full Text] [Related]
45. An assessment of the immunological status of patients with renal cell carcinoma based on the relative abundance of T-helper 1- and -2 cytokine-producing CD4+ cells in peripheral blood.
Onishi T; Ohishi Y; Goto H; Tomita M; Abe K
BJU Int; 2001 Jun; 87(9):755-9. PubMed ID: 11412209
[TBL] [Abstract][Full Text] [Related]
46. Intratumoral submicron particle docetaxel inhibits syngeneic Renca renal cancer growth and increases CD4+, CD8+, and Treg levels in peripheral blood.
Maulhardt HA; Marin AM; diZerega GS
Invest New Drugs; 2020 Oct; 38(5):1618-1626. PubMed ID: 32198648
[TBL] [Abstract][Full Text] [Related]
47. Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts.
Wang J; Nakamoto T; Kasaoka Y; Usui T; Hamada H
Hiroshima J Med Sci; 2000 Mar; 49(1):73-82. PubMed ID: 10824460
[TBL] [Abstract][Full Text] [Related]
48. Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources.
Gregorian SK; Battisto JR
Cancer Immunol Immunother; 1990; 31(6):325-34. PubMed ID: 2386978
[TBL] [Abstract][Full Text] [Related]
49. Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.
Westwood JA; Darcy PK; Guru PM; Sharkey J; Pegram HJ; Amos SM; Smyth MJ; Kershaw MH
J Transl Med; 2010 Apr; 8():42. PubMed ID: 20426873
[TBL] [Abstract][Full Text] [Related]
50. CD8+ T lymphocytes regulating Th2 pathology escape neonatal tolerization.
Adams B; Nagy N; Paulart F; Vanderhaeghen ML; Goldman M; Flamand V
J Immunol; 2003 Nov; 171(10):5071-6. PubMed ID: 14607904
[TBL] [Abstract][Full Text] [Related]
51. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
[TBL] [Abstract][Full Text] [Related]
52. Th1-cytokine induction and anti-tumor effect of 55 kDa protein isolated from Aeginetia indica L., a parasitic plant.
Ohe G; Okamoto M; Oshikawa T; Furuichi S; Nishikawa H; Tano T; Uyama K; Bando T; Yoshida H; Sakai T; Himeno K; Sato M; Ohkubo S
Cancer Immunol Immunother; 2001 Jul; 50(5):251-9. PubMed ID: 11499808
[TBL] [Abstract][Full Text] [Related]
53. Tumor-specific targeting of T helper type 1 (Th1) cells by anti-CD3 x anti-c-ErbB-2 bispecific antibody.
Ohmi Y; Shiku H; Nishimura T
Cancer Immunol Immunother; 1999 Nov; 48(8):456-62. PubMed ID: 10550550
[TBL] [Abstract][Full Text] [Related]
54. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
55. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
[TBL] [Abstract][Full Text] [Related]
56. CD8+ T cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and, combined with GM‑CSF and IL‑12, enhance the anti‑renal cortical adenocarcinoma effect.
Xu HY; Li N; Yao N; Xu XF; Wang HX; Liu XY; Zhang Y
Oncol Rep; 2019 Aug; 42(2):866-879. PubMed ID: 31233203
[TBL] [Abstract][Full Text] [Related]
57. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
58. Tumor site-dependent differential modulation of systemic immunity in RENCA bearing mice.
Yoon HL; Choi KM; Jung YS; Park CH; Yoon SS
In Vivo; 1999; 13(5):407-13. PubMed ID: 10654194
[TBL] [Abstract][Full Text] [Related]
59. A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer.
Berlato C; Khan MN; Schioppa T; Thompson R; Maniati E; Montfort A; Jangani M; Canosa M; Kulbe H; Hagemann UB; Duncan AR; Fletcher L; Wilkinson RW; Powles T; Quezada SA; Balkwill FR
J Clin Invest; 2017 Mar; 127(3):801-813. PubMed ID: 28134623
[TBL] [Abstract][Full Text] [Related]
60. IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response.
Adris S; Klein S; Jasnis M; Chuluyan E; Ledda M; Bravo A; Carbone C; Chernajovsky Y; Podhajcer O
Gene Ther; 1999 Oct; 6(10):1705-12. PubMed ID: 10516719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
